FreshRecalls

⚠ Data freshness notice: the most recent refresh of NHTSA was incomplete, so a very recent recall may be missing. Everything shown is accurate as of the last checked time on this page — for anything time-critical, confirm with the official sources linked below.

FDAClass II · Drug · Recalled June 24, 2026

Med Pride recall — Dabur India Limited

Hazard: CGMP Deviations; deficiencies observed during FDA inspection

Class II: may cause temporary or medically reversible health consequences.

View the official FDA enforcement record (openFDA) ↗

Official recall ID
D-0641-2026
Brand
Dabur India
Classification
Class II
Units affected
3006 tubes
Recall status
Ongoing
Initiated
Voluntary: Firm initiated

Description

Med Pride, Triple Antibiotic Ointment, Bacitracin Zinc (equivalent to 400 units), Neomycin Sulfate 5 mg, Polymixin B 5000 units, 0.9g packets, 144 packets per box, 130g, Manufactured for: Shield Line LLC, 59 Hook Road, Bayonne, NJ 07002 USA, Made in India, UPC 1 03 52410 30253 1.

Affected products

Companies & origin

Recalling firm location
Dadra And Nagar Haveli, India
Firm address
225 - 4 - 1 Saily Village, Survey No, N/A

Identifying details (verbatim from the notice)

Product codes / lots
Lot# 011, 014, 015, 016, 017, 018, 019, 020, 021, 022, 026, Within Expiry.
Distribution
US Nationwide.
Firm notified the public via
E-Mail
FDA event ID
99137
Recall initiated
June 2, 2026
FDA classified
June 26, 2026
FDA report date
June 24, 2026

Source: U.S. Food & Drug Administration. This page mirrors the official public-domain record verbatim; the linked government source is authoritative. Source last checked July 23, 2026 at 11:04 PM UTC.

Report a data error on this page